๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Validity of the Short-Memory Questionnaire in vascular dementia

โœ Scribed by Naruhiko Maki; Manabu Ikeda; Kazuhiko Hokoishi; Akihiko Nebu; Kenjiro Komori; Kazue Shigenobu; Ryuji Fukuhara; Nobutsugu Hirono; Hideki Nakata; Hirotaka Tanabe

Publisher
John Wiley and Sons
Year
2000
Tongue
English
Weight
69 KB
Volume
15
Category
Article
ISSN
0885-6230

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

A COMPARISON OF SEMANTIC MEMORY IN VASCU
A COMPARISON OF SEMANTIC MEMORY IN VASCULAR DEMENTIA AND DEMENTIA OF ALZHEIMER'S TYPE
โœ PETER W. BENTHAM; STEPHEN JONES; JOHN R. HODGES ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 112 KB ๐Ÿ‘ 2 views

Objective. To determine whether semantic memory is impaired in vascular dementia and to assess the utility of semantic memory measures in dierentiating vascular dementia from dementia of Alzheimer's type (DAT). Design. Case-control study. Patients. Ten patients with Cambridge Mental Disorders in t

Interrater reliability of the short-memo
Interrater reliability of the short-memory questionnaire in a variety of health professional representatives
โœ Naruhiko Maki; Manabu Ikeda; Kazuhiko Hokoishi; Michie Nomura; Shiho Torikawa; N ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 64 KB ๐Ÿ‘ 1 views

A study was performed to assess interrater reliability of the Japanese version of the Short-Memory Questionnaire (SMQ), which is an easily-administered, informant-based scale of cognitive function. The subjects were 18 consecutive patients with Alzheimer's disease who were outpatients of Department

A crossover trial of bromocriptine in th
A crossover trial of bromocriptine in the treatment of vascular dementia
โœ Dr. Stephen E. Nadeau; Paul F. Malloy; Michael E. Andrew ๐Ÿ“‚ Article ๐Ÿ“… 1988 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 342 KB ๐Ÿ‘ 1 views

Seven patients with vascular dementia completed an 8month randomized double-blind crossover trial of bromocriptine i n a dosage of u p to 30 mg per day. Patients were assessed using a modified UCLA Parkinson Rating Scale of symptoms and signs, and neuropsychological testing including the Wechsler Ad